Placeholder Banner

5 Business Panels at BIO CEO Conference in NYC

February 2, 2010
Next week's BIO CEO investor conference in New York will be hosting five business panels on topics from M&A, IPOs, FOPOs, PIPEs, and Venture Capital to stock market trends and predictions for 2010:

Roundtable: M&A: Prospects for 2010

Monday, Feb. 8, 12:00 p.m. - 1:00 p.m.



Christopher Wasden, Managing Director, Advisory Pharmaceutical and Life Sciences, PricewaterhouseCoopers (moderator)

  • Tracy Lefteroff, Global Leader, Life Sciences Industry Services, PricewaterhouseCoopers

  • David A. Levin, Managing Director, Mergers & Acquisitions, Deutsche Bank Securities, Inc

  • Brent Saunders, Special Advisor, General Atlantic, Former, President, Global Consumer Health Care, Schering-Plough Corp

  • Stephen M. Simes, President & CEO, BioSante Pharmaceuticals, Inc.

  • Barbara Yanni, Vice President & Chief Licensing Officer, Merck & Co. Inc.




Roundtable: Capital Markets 360°

Monday, Feb. 8, 1:30 p.m. - 2:30 p.m.

Stephen Sands, Managing Director, Vice Chairman and Global Co-Head Healthcare Investment Banking, Lazard (moderator)

  • Paul B. Cleveland, Chief Financial Officer & Executive Vice President, Corporate Development, Affymax, Inc.

  • Richard Gormley, Managing Director, Head of the Alternative Capital Finance Group, Lazard

  • David E. Kroin, Co-Founder, Managing Director, Great Point Partners

  • Graham Powis, Managing Director, Head of U.S. Equity Capital Markets, Lazard


Roundtable: Alternative Financing Strategies: Follow-Ons, PIPEs & Private Placements

Tuesday, Feb. 9, 10:30 a.m. - 11:30 a.m.



Joseph A. Smith, Partner, Corporate & Securities, WeinsteinSmith, LLP (moderator)

  • Benjamin R. Bowen, Ph.D., Managing Director, Investment Banking, Rodman & Renshaw, LLC

  • Susanne S. Mulligan, Co-Head, Private Equity, Placements & PIPEs, Equity Capital Markets, Health Care Origination, Deutsche Bank Securities, Inc.

  • Matthew J. Pfeffer, Corporate Vice President and Chief Financial Officer, MannKind Corporation

  • Rajesh Shrotriya , M.D., Chairman, Chief Executive Officer and President, Spectrum Pharmaceuticals

  • H. Thomas Watkins, President and Chief Executive Officer, Human Genome Sciences


Roundtable: Business Development: 4th & Goal – Are You Ready to Go Commercial?

Tuesday, Feb. 9, 12:00 p.m. - 1:00 p.m.



Ben Bonifant, Vice President, Business Development Practice, Campbell Alliance (moderator)

  • Ron Cohen, M.D., President & Chief Executive Officer, Acorda Therapeutics

  • Mitchell H. Gold, M.D., President & Chief Executive Officer, Dendreon Corporation

  • Jay D. Kranzler, M.D., Ph.D, Chief Executive Officer & Chairman of the Board, Cypress Bioscience Inc.

  • John R. Leone, Partner, Paul Capital


Closing Plenary: The Unconventional Wisdom—Thoughts for a New Decade

Tuesday, Feb. 9, 4:30 p.m. - 5:30 p.m.



George Milstein, Managing Director, Healthcare Mergers and Acquisitions, Wedbush PacGrow Life Sciences (moderator)

  • David Farhadi, M.D., Portfolio Manager, Fred Alger Management

  • Rajiv Kaul, Portfolio Manager/Research Analyst, Fidelity Investments

  • Dennis Purcell, Senior Managing Partner, Aisling Capital, LLC

  • David Sable, M.D., Life Sciences Portfolio Manager, Special Situations Funds

  • Nathan Sadeghi-Nejad, Director, Highside Capital Management


12th Annual BIO CEO & Investor Conference
February 8-9, 2010
New York, NY